WEDNESDAY, Nov. 27, 2024 (HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial resultsContinue Reading

TUESDAY, Nov. 26, 2024 (HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.  Right now, a law passed byContinue Reading